Sensus Healthcare Inc. Common Stock (SRTS)
StalwartFairStock Score: 36/100 — MIXED
Key Financials
| Current Price | $3.61 |
| Market Cap | $65M |
| P/E Ratio | -7.68 |
| ROE | -14.85% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $4 million in annual free cash flow (6.0% yield on market cap)
- Conservative balance sheet with debt-to-equity of just 0.01, providing financial flexibility
- Altman Z-Score of 8.9 confirms minimal bankruptcy risk and strong solvency
Concerns
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
- Revenue declining at 62.2% year-over-year signals potential demand weakness or market share loss
- Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
AI Analysis
Sensus Healthcare Inc. Common Stock is a micro-cap healthcare company valued at $65 million. Revenue stands at $27 million, though the company is currently unprofitable. From a quality standpoint, Sensus shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 8.9 confirms fortress-level solvency. Growth dynamics show revenue growing at -62.2% and profit growth of -304.9%. Our composite FairStock Score of 36/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $4 million in annual free cash flow (6.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer